Skip to main content
SpringerLink
Log in

Quality of Life as an Outcome in Breast Cancer

Clinical Application

  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

In clinical trials of anticancer agents, the assessment of objective effects has historically been the primary end-point. However, because of the limited impact of these agents on survival, the study of quality of life (QOL) has become increasingly important. QOL evaluation is difficult and the approaches of physicians and reimbursors of healthcare are quite different. In addition, QOL is not a simple concept and several different methods have been used to evaluate it. These methods can be divided into the following 2 groups: experimental methods [the best known is the quality-adjusted life-year (QALY)], which utilise some kind of experimentation; and observational methods, which use questionnaires and are often multifactorial. Some of these questionnaires are used for patients with all types of pathologies, while others are cancer-specific; all questionnaires must be validated.

We conducted 3 QOL studies in patients with breast cancer using the Functional Living Index-Cancer (FLIC) questionnaire. In the first, a French translation of the FLIC questionnaire was validated. The FLIC and Functional Living Index-Emesis (FLIE) questionnaires were used to assess QOL in a second study comparing 2 different antiemetics for the control of nausea and vomiting. Finally, QOL was evaluated in patients with breast cancer during adjuvant chemotherapy. Several other studies employing different questionnaires in patients with breast cancer have been published.

Clinical applications for QOL evaluation in oncology may be the prognostic implications of QOL, evaluation of toxicity and duration of treatment, and evaluation of utility and QOL. However, although assessment of QOL is important for both physicians and funders, there is no gold standard method available, and the results of QOL studies have to be interpreted cautiously.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aaronson NK. Methodologic issues in assessing the quality of life of cancer patients. Cancer 1991; 67(3): 844–50

    Article  PubMed  CAS  Google Scholar 

  2. Flanagan JC. Measurement of quality of life: current state of the art. Arch Phys Med Rehabil 1982; 63: 56–9

    PubMed  CAS  Google Scholar 

  3. Caiman KC. Quality of life in cancer patients — an hypothesis. J Med Ethics 1984; 10: 124–7

    Article  Google Scholar 

  4. Auray JP, Duru G, Lamure M. Réflexions sur les indicateurs de qualité de vie. Communication Partenaires Santé 1993; no. spécial: Evaluation médico-économique des stratégies diagnostiques et thérapeutiques: 25–39

  5. Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ 1986; 5: 1–30

    Article  PubMed  CAS  Google Scholar 

  6. Mehrez A, Gafni A. Quality adjusted life years, utility theory and healthy-years equivalent. Med Decis Making 1989; 9: 806–27

    Article  Google Scholar 

  7. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5: 559–75

    Article  PubMed  CAS  Google Scholar 

  8. Spilker B. Quality of life: assessments in clinical trials. New York: Raven Press, 1990: 470

    Google Scholar 

  9. McEwen J. The Nottingham Health Profile. In: Walker SR, Rosen MR, editors. Quality of life assessment and application. Lancaster: MTP Press Ltd, 1987

    Google Scholar 

  10. Ware JE Jr. Overview of general health measures used in the Rand Health Insurance Experiment. Presented at the first national meeting of the Association of Health Services Research. Chicago: June 1984

  11. Bergner M, Bobitt RA, Caeter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805

    Article  PubMed  CAS  Google Scholar 

  12. Chambers LW. The McMaster Health Index questionnaire: an update. In: Walker SR, Rosser RM, editors. Quality of life: assesssment and application. Lancaster: MTP Press Ltd, 1987

    Google Scholar 

  13. Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients. The Functional Living Index-Cancer: development and validation. J Clin Oncol 1984; 2(5): 472–83

    PubMed  CAS  Google Scholar 

  14. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Nat Cancer Inst 1993; 85(5): 365–76

    Article  PubMed  CAS  Google Scholar 

  15. Donovan K, Sanson-Fisher RW, Redman S. Measuring quality of life in cancer patients. J Clin Oncol 1989; 7: 959–68

    PubMed  CAS  Google Scholar 

  16. Fayers PM, Jones SDR. Measuring and analyzing the quality of life in cancer clinical trials: a review. Stat Med 1983; 2: 429–46

    Article  PubMed  CAS  Google Scholar 

  17. Van Knippenberg FCE, De Haes JCJM. Measuring the quality of life of cancer patients: psychometric properties of instruments. J Clin Epidemiol 1988; 42(1): 1043–53

    Article  Google Scholar 

  18. McMillen-Moinpour C, Feigl P, Metch B, et al. Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst 1989; 81(7): 485–95

    Article  Google Scholar 

  19. Joseph A, Chicoye A, Bonneterre J. Un outil d’évaluation de la qualité de vie. In: Les outils de l’évaluation en cancérologie: aspects méthodologiques. Journées d’étude de la Société Française d’évaluation des soins et des technologies. Villejuif: 27 avril 1992: 31–6

    Google Scholar 

  20. Clavel M, Bonneterre J, d’Aliens H, et al. Oral ondansetron in the prevention of chemotherapy induced emesis in breast cancer patients. Eur J Cancer 1995; 31A(1): 15–9

    Article  PubMed  CAS  Google Scholar 

  21. Crépin G, Bonneterre J, Duquenne I. Quality of life in breast cancer patients receiving adjuvant therapy. Fédération Internationale de Gynécologie Obstétrique, Montréal: 1994 septembre 24–28

  22. Priestman TJ, Baum M. Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1976; 1: 899–900

    Article  PubMed  CAS  Google Scholar 

  23. Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987; 317: 1490–5

    CAS  Google Scholar 

  24. Levine MN, Guyatt GH, Gent M, et al. Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol 1988; 6: 1798–1810

    PubMed  CAS  Google Scholar 

  25. Goldhirsch A, Gelber RD, Simes RJ, et al. For the Ludwig Breast Cancer Study Group. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 1989; 7: 36–44

    CAS  Google Scholar 

  26. Gelber RD, Goldhirsch A. For the Ludwig Breast Cancer Study Group. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 1986; 4: 1772–9

    CAS  Google Scholar 

  27. Ware JE, Brook RB, Davies-Avery A, et al. Conceptualisation and measurement of health of adults in the Health Insurance Study. Vol I. Model of health and methodology. Santa Monica: Rand Corporation; 1980

    Google Scholar 

  28. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients. J Chron Dis 1981; 34: 585–97

    Article  PubMed  CAS  Google Scholar 

  29. Fayers PM, Bleehen NM, Girling DJ, et al. Assessment of quality of life in small-cell lung cancer using a daily diary card developed by the medical research council lung cancer working party. Br J Cancer 1991; 64: 299–306

    Article  PubMed  CAS  Google Scholar 

  30. Hurny C, Bernhard J, Joss R, et al. Feasibility of quality of life assessment in a randomized phase HI trial of small cell lung cancer. A lesson from the real world. Ann Oncol 1992; 3: 825–31

    CAS  Google Scholar 

  31. Ganz PA, Haskell CM, Figlin RA, et al. Estimating the quality of life in clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index-Cancer. Cancer 1988; 61: 849–56

    Article  PubMed  CAS  Google Scholar 

  32. Coates A, Gebski V, Signorini D. Prognostic value of quality of life scores during chemotherapy for advanced breast cancer. J Clin Oncol 1992; 10(12): 1833–8

    PubMed  CAS  Google Scholar 

  33. Coates A. Prognostic implications of quality of life. Cancer Treat Rev 1993; 19 Suppl. A: 53–7

    Article  PubMed  Google Scholar 

  34. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 1991; 67: 3131–5

    CAS  Google Scholar 

  35. Ruckdeschel JC, Piantadosi S, the Lung Cancer Study Group. Quality of life assessment in lung surgery for bronchogenic carcinoma. Theor Surg 1991; 6: 201–5

    Google Scholar 

  36. Geddes DM, Dones L, Hill E, et al. Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial. Eur J Cancer 1990; 26(4): 484–92

    Article  PubMed  CAS  Google Scholar 

  37. Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. PharmacoEconomics 1996; 9 Suppl. 2: 8–22

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Oscar Lambret, 1 rue Frédéric Combenale, BP 307, 59020, Lille, France

    Jacques Bonneterre & S. Lecomte

  2. Centre Hospitalier Universitaire de Besançon, Besançon, France

    S. Schraub & M. Mercier

Authors
  1. Jacques Bonneterre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Schraub
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Lecomte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Mercier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonneterre, J., Schraub, S., Lecomte, S. et al. Quality of Life as an Outcome in Breast Cancer. Pharmacoeconomics 9 (Suppl 2), 23–29 (1996). https://doi.org/10.2165/00019053-199600092-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199600092-00005

Keywords

Search

Navigation